Authors
Beldiev S. N.
PhD, Associate Professor, Chair for Hospital Therapy and Occupational Diseases
ORCID 0000-0002-0831-6320
Egorova I. V.
PhD, Associate Professor, Chair for Hospital Therapy and Occupational Diseases
ORCID 0000-0002-2188-8366
Koveshnikov A. I.
PhD, Associate Professor, Chair for Hospital Therapy and Occupational Diseases
ORCID 0000-0002-1727-8952
Platonov D. Yu.
MD, PhD, MPH, Professor, Chair for Hospital Therapy and Occupational Diseases
ORCID 0000-0003-0635-3571
Tver State Medical University, Tver, Russian Federation
Corresponding Author
Beldiev Sergey; e-mail: sbeldiev@yandex.ru
Conflict of interest
Authors have no conflict of interest.
Funding
The study had no sponsorship.
Abstract
The Anticholinergic Cognitive Burden (ACB) scale, developed in the United States and the United Kingdom in 2008/2012, has been recommended for use in national clinical practice since 2016. Comparison with the original ACB scale shows that in the national educational and methodological literature of 2016/2018 it has been presented in a significantly shortened and partially distorted form. In the 2024 methodological guide, the previously presented national version of ACB scale has been modified again by further reducing the list of drugs with the score of 1 and including in the list of drugs with score of 3 those with strong anticholinergic properties from the 2023 Beers criteria list. In all publications, the ACB scale description has been accompanied by incorrect bibliographic references, and the feasibility of its practical application has been justified by the study of another scale (ARS: Anticholinergic Risk Scale), as well as by the incorrectly presented results of the ACB scale studies. As a consequence, the readers remain uninformed that the use of drugs with the score of 1, primarily cardiovascular drugs, was not associated with the increased risk of developing cognitive impairment in the ACB scale studies.
Key words
anticholinergics, Anticholinergic Cognitive Burden (ACB) scale, Anticholinergic Risk Scale (ARS), Beers criteria
DOI
References
1. Boustani M., Campbell N., Munger S., Maidment I., Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 2008; 4(3): 311-320, doi: 10.2217/1745509X.4.3.311
2. Campbell N.L., Maidment I., Fox C., Khan B., Boustani M. The 2012 update to the anticholinergic cognitive burden scale. J Am Geriatr Soc 2013;61(S1):S142-S143. C46, doi: 10.1111/jgs.2013.61.issue-s1.
3. Anticholinergic Cognitive Burden scale. 2012 Update. Developed by the Aging Brain Program of the Indiana University Center for Aging Research. Available at: https://corumpharmacy.com/wp-content/uploads/2020/08/Anticholinergiccognitive-burden-scale.pdf. Accessed: March 10, 2025.
4. Sychev D.A., Orekhov R.E. Shkala antiholinergicheskoj nagruzki kak metod bor'by s polipragmaziej u pacientov pozhilogo i starcheskogo vozrasta [Anticholinergic cognitive burden scale as a method of fighting polypharmacy in elderly and senile patients]. Klinicheskaya Farmakologiya i Terapiya [Clinical pharmacology and therapy] 2016; 25(4): 81-84. (In Russ.)
5. Sychev D.A. (editor). Polipragmazija v klinicheskoj praktike: problema i reshenija. Uchebnoe posobie [Polypharmacy in clinical practice: problems and solutions. Study guide]. Saint Petersburg: TsOP Profession; 2016. (In Russ.)
6. Sychev D.A. (editor). Polipragmazija v klinicheskoj praktike: problema i reshenija. Uchebnoe posobie. 2-e izd., ispr. i dop. [Polypharmacy in clinical practice: problems and solutions. Study guide. 2nd edition corrected and supplemented]. Saint Petersburg: TsOP Profession; 2018. 272 p. (In Russ.)
7. Tkacheva O.N., Nedogoda S.V., Arutyunov G.P., Boytsov S.A., Vertkin A.L., Villevalde S.V. et al. Metodicheskie rukovodstva: Farmakoterapija u lic pozhilogo i starcheskogo vozrasta. [Methodological guidelines: Pharmacotherapy in elderly and senile individuals]. 2018. Available at: https://apicr.minzdrav.gov.ru/Files/recomend/MP103.PDF. Accessed: March 10, 2025. (In Russ.)
8. Sychev D.A., Tkacheva O.N., Kotovskaya Yu.V., Malaya I.P. Farmakoterapija u lic pozhilogo i starcheskogo vozrasta. Metodicheskoe rukovodstvo. [Pharmacotherapy in elderly and senile individuals. Methodological guidelines]. Moscow: OOO KONGRESSKHIM; 2024. Available at: https://rgnkc.ru/images/metod_materials/Farmakoterapiya_2018.pdf. Accessed: March 10, 2025. (In Russ.)
9. Ostroumova O.D., Kulikova M.I., Sychev D.A., Golovina O.V., Chernyaeva M.S. Vlijanie lekarstvennyh preparatov s antiholinergicheskoj aktivnost'ju na kognitivnye funkcii pacientov 80 let i starshe s jessencial'noj arterial'noj gipertenziej [The effect of anticholinergic medications on cognitive function of patients 80 years and older with essential hypertension]. Arterial’naya Gipertenziya [Arterial Hypertension]. 2019; 25(3): 246-257, doi: 10.18705/1607-419X-2019-25-3-246-257. (In Russ.)
10. Al-Rajawi A.M., Zyryanov S.K., Ushkalova E.A., Butranova O.I., Pereverzev A.P. Associaciya antiholinergicheskoi kognitivnoj nagruzki s naznacheniem potencial’no ne rekomendovannyh lekarstvennyh sredstv I chastoi gospitalizacii pacientov pozhilogo I starcheskogo vozrasta. [Association of anticholinergic cognitive load with the appointment of potentially not recommended drugs and the frequency of hospitalization of elderly and senile patients.] Kachestvennaya Klinicheskaya Praktika [Good Clinical Practice]. 2019; (2): 85-94, doi: 10.24411/2588-0519-2019-10076. (In Russ.)
11. Shatalova N.A., Batyukina S.V., Chernyaeva M.S., Kochetkov A.I., Ebzeeva E.Yu., Ostroumova O.D. Antiholinergicheskaja nagruzka u pacientov s fibrilljaciej predserdij [Anticholinergic burden in patients with atrial fibrillation]. Jeffektivnaja farmakoterapija [Effective Pharmacotherapy] 2022; 18(40): 16-21, doi: 10.33978/2307-3586-2022-18-40-16-21. (In Russ.)
12. Ostroumova O.D., Dzamikhov K.K., Kochetkov A.I., Ostroumova Ò.M., Ebzeyeva E.Yu., Andrianov À.I., et al. Antiholinergicheskaja nagruzka i sostojanie kognitivnyh funkcij u pacientov pozhilogo i starcheskogo vozrasta s arterial'noj gipertenziej [Anticholinergic burden and the cognitive functions in elderly and senile patients with arterial hypertension]. Medicinskij alfavit [Medical alphabet] 2024; (13): 68-73, doi: 10.33667/2078-5631-2024-13-68-73 (In Russ.)
13. Chew M.L., Mulsant B.H., Pollock B.G., Lehman M.E., Greenspan A., Mahmoud R.A., et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56(7): 1333-1341, doi: 10.1111/j.1532-5415.2008.01737.x
14. Campbell N.L., Boustani M.A., Lane K.A., Gao S., Hendrie H., Khan B.A., et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology 2010; 75(2): 152-159, doi: 10.1212/WNL.0b013e3181e7f2ab
15. Fox C., Richardson K., Maidment I.D., Savva G.M., Matthews F.E., Smithard D., et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 59(8): 1477-1483, doi: 10.1111/j.1532-5415.2011.03491.x
16. By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2023; 71(7): 2052-2081, doi: 10.1111/jgs.18372
17. Rudolph J.L., Salow M.J., Angelini M.C., McGlinchey R.E. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168(5): 508-513, doi: 10.1001/archinternmed.2007.106
18. Han L., McCusker J., Cole M., Abrahamowicz M., Primeau F., Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161(8): 1099-1105, doi: 10.1001/archinte.161.8.1099
19. Samsa G.P., Hanlon J.T., Schmader K.E., Weinberger M., Clipp E.C., Uttech K.M., et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994; 47(8): 891-896, doi: 10.1016/0895-4356(94)90192-9
20. Jansen P.A., Brouwers J.R. Clinical pharmacology in old persons. Scientifica (Cairo) 2012; 2012: 723678, doi: 10.6064/2012/723678
21. Carnahan R.M., Lund B.C., Perry P.J., Pollock B.G., Culp K.R. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 2006; 46(12): 1481-1486, doi: 10.1177/0091270006292126
22. Ostroumova O.D., Kulikova M.I., Ostroumova T.M., Chernyaeva M.S., Kochetkov A.I., Parfenov V.A. Lekarstvenno-inducirovannye kognitivnye narushenija. [Drug-induced cognitive impairment]. Nevrologija, nejropsihiatrija, psihosomatika [Neurology, Neuropsychiatry, Psychosomatics] 2020; 12(3): 11-18, doi: 10.14412/2074-2711-2020-3-11-18 (In Russ.)
23. Shalygin V.A., Sinitsina I.I., Savelyeva V.A., Ilyina E.S., Sychev D.A. Kliniko-farmakologicheskie podhody k prognozirovaniju riska padenij u pozhilyh. [Predicting the risk of falls in the elderly]. Klinicheskaya Farmakologiya i Terapiya [Clinical pharmacology and therapy] 2020; 29(1): 75-79, doi: 10.32756/0869-5490-2020-1-75-79 (In Russ.)
24. Pereverzev A.P. Central'nye nezhelatel'nye reakcii NPVS [Central adverse drug reactions of NSAIDs]. Medicinskij alfavit [Medical alphabet] 2021; (36): 18-24, doi: 10.33667/2078-5631-2021-36-18-24 (In Russ.)
25. Ruxton K., Woodman R.J., Mangoni A.A. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis. Br J Clin Pharmacol 2015; 80(2): 209-220, doi: 10.1111/bcp.12617
26. Carrière I., Fourrier-Reglat A., Dartigues J.F., Rouaud O., Pasquier F., Ritchie K., et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study. Arch Intern Med 2009; 169(14): 1317-1324, doi: 10.1001/archinternmed.2009.229
27. Whalley L.J., Sharma .S, Fox H.C., Murray A.D., Staff R.T., Duthie A.C., et al. Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia. J Alzheimers Dis 2012; 30(2): 253-261, doi: 10.3233/JAD-2012-110935
28. Gallagher P., O'Mahony D. STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria. Age Ageing 2008; 37(6): 673-679, doi: 10.1093/ageing/afn197
29. Kwan D., Farrell B. Polypharmacy: optimizing medication use in elderly patients. Canadian Geriatrics Society Journal of CME 2014; 4(1): 21-27.
30. Handler S.M., Hanlon J.T., Perera S., Roumani Y.F., Nace D.A., Fridsma D.B., et al. Consensus list of signals to detect potential adverse drug reactions in nursing homes. J Am Geriatr Soc 2008; 56(5): 808-815, doi: 10.1111/j.1532-5415.2008.01665.x
31. Beldiev S.N., Lazdin O.A., Egorova I.V., Platonov D.Yu. Obosnovanie gipolipidemicheskoj jeffektivnosti ursodezoksiholevoj kisloty v otechestvennyh klinicheskih rekomendacijah: prevrashhenie peshki v ferzja. [Justification of lipid-lowering efficacy of ursodeoxycholic acid in national clinical guidelines: transformation a pawn into a queen]. Verhnevolzhskij medicinskij zhurnal [Upper Volga Medical Journal] 2017; 16(4): 37-41. (In Russ.)
32. Beldiev S.N., Egorova I.V., Platonov D.Yu. Rekomendacii po primeneniju peroral'nyh antikoaguljantov u pacientov pozhilogo vozrasta: kriterii Birsa i dokazatel'naja medicina [Recommendations on the use of oral anticoagulants in elderly patients: Beers criteria and evidence-based medicine]. Medicina [Medicina] 2019; 7(4): 1-11, doi: 10.29234/2308-9113-2019-7-4-1-11 (In Russ.)
33. Beldiev S.N., Trufanova G.Yu., Medvedeva I.V., Egorova I.V., Berezina E.I., Platonov D.Yu. Primenenie citizina dlja lechenija tabachnoj zavisimosti: kommentarii k Nacional'nomu rukovodstvu po profilaktike hronicheskih neinfekcionnyh zabolevanij. [Cytisine use for tobacco addiction treatment: comments on the Russian guidelines for prevention of chronic non-communicable diseases]. Medicina [Medicina] 2022; 10(3): 13-28, doi: 10.29234/2308-9113-2022-10-3-13-28. (In Russ.)
